Results 71 to 80 of about 26,034 (198)

Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. [PDF]

, 2016
Alemtuzumab is an anti-CD52 monoclonal antibody recently licensed for use in relapsing-remitting multiple sclerosis. Here, we report our experience of its use in neuromyelitis optica (NMO) spectrum disorders.
Azzopardi, L, Coles, AJ, Cox, AL, Jones, JL, McCarthy, CL   +4 more
core   +1 more source

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real‐World Evidence

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare the long‐term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS). Methods Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from
Gabriel Cerono, Bruce A.C. Cree, Stephen L. Hauser, Sergio E. Baranzini   +3 more
wiley   +1 more source

From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis

Annals of Neurology, EarlyView.
Objective The growing demand for personalized treatment in multiple sclerosis (MS) highlights the need for more precise biomarkers that can outperform magnetic resonance imaging and clinical assessment in patient stratification. Advances in multiplex proteomic technologies suggest that cerebrospinal fluid (CSF) analysis at MS onset may not only improve
Laura Ghezzi, Peter Kosa, Mark Greenwood, Enrique Alvarez, C.L. Freedman, Anne H. Cross, Francesca Pace, Mark S. Freedman, Joanna Kocot, Laura Piccio, Bibiana Bielekova   +10 more
wiley   +1 more source

Tonic spasms are a common clinical manifestation in patients with neuromyelitis optica

Arquivos de Neuro-Psiquiatria, 2013
Tonic spasms have been most commonly associated with multiple sclerosis. To date, few reports of series of patients with neuromyelitis optica and tonic spasms have been published.
Luz Abaroa, Sergio A. Rodríguez-Quiroga, Luciana Melamud, Tomoko Arakaki, Nelida S. Garretto, Andres M. Villa   +5 more
doaj   +1 more source

Effects of physical therapy intervention in the management of neuromyelitis optica: a case report

Bulletin of Faculty of Physical Therapy, 2023
Background Neuromyelitis optica is a rare immune-mediated demyelinating central nervous system disorder affecting the spinal cord and optic nerves. There is no permanent cure for this disease, and its management requires a multidisciplinary approach ...
Sneha Chakraverty, Sayak Dutta, Himadri Das   +2 more
doaj   +1 more source

Plasma complement biomarkers distinguish multiple sclerosis and neuromyelitis optica spectrum disorder [PDF]

, 2016
Background: Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are autoimmune demyelinating diseases distinguished clinically by selective involvement in NMOSD of optic nerves and spinal cord. Early clinical manifestations are
Evans, David R. S., Hakobyan, Svetlana, Harding, Katharine, Loveless, Samantha, Luppe, Sebastian, Morgan, Bryan Paul, Robertson, Neil P.   +6 more
core   +1 more source

Myelitis‐Predominant Aggressive Phenotype: Unveiling Unique Patterns of Late‐Onset Neuromyelitis Optica Spectrum Disorders

Annals of Neurology, EarlyView.
Objective The objective of this study was to compare clinical features and prognosis of late‐onset neuromyelitis optica spectrum disorder (LO‐NMOSD, onset age ≥60 years) with adult‐onset NMOSD (AO‐NMOSD, onset age 18–59 years), and to provide insights for individualized management in elderly patients.
Ya‐Lan Pu, Jin‐Zhou Feng, Hua‐Xing Meng, Hai‐Bing Xiao, Xiao‐Ling Li, Jin Zhen, Wen‐Ying Lu, Xu‐Ming Xi, Ti Wu, Bao‐Shi Yuan, Mo‐Li Fan, Chao Zhang, De‐Cai Tian, Xia Meng, Fu‐Dong Shi, Tian Song   +15 more
wiley   +1 more source

Breast cancer-associated paraneoplastic neuromyelitis optica with cervical cord compression and spondylosis requiring laminectomy: A case report

SAGE Open Medical Case Reports, 2023
Neuromyelitis optica, an autoimmune inflammatory disorder affecting the central nervous system, can occur in a paraneoplastic context, although rare.
Bahadar S Srichawla, Shravan Sivakumar, Seyedeh N Cheraghi, Vincent Kipkorir, Maria A Garcia-Dominguez   +4 more
doaj   +1 more source

Anti-aquaporin 4 IgG Is Not Associated With Any Clinical Disease Characteristics in Neuromyelitis Optica Spectrum Disorder

Frontiers in Neurology, 2021
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a clinically defined, inflammatory central nervous system (CNS) disease of unknown cause, associated with humoral autoimmune findings such as anti-aquaporin 4 (AQP4)-IgG.
Oliver Schmetzer, Oliver Schmetzer, Oliver Schmetzer, Elisa Lakin, Elisa Lakin, Elisa Lakin, Ben Roediger, Ankelien Duchow, Ankelien Duchow, Ankelien Duchow, Susanna Asseyer, Susanna Asseyer, Susanna Asseyer, Friedemann Paul, Friedemann Paul, Friedemann Paul, Nadja Siebert, Nadja Siebert, Nadja Siebert   +18 more
doaj   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger, Hannah F. Todd, Jonathan M. Yarimi, Timothy E. Lotze, Nikita M. Shukla, Kristen S. Fisher, Alexander J. Sandweiss   +6 more
wiley   +1 more source